Jaguar Health Presents Oral Liquid Crofelemer Efficacy at ESPGHAN Meeting

Jaguar Health provided a recap of presentations of the oral liquid crofelemer as adjunctive therapy in pediatric intestinal failure, IF, patients at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition, ESPGHAN, Meeting in Lille, France. Napo provided additional data from ongoing investigational studies with oral liquid crofelemer in pediatric patients with IF due to microvillus inclusion disease, MVID, and short bowel syndrome, SBS. Since IF patients cannot orally absorb adequate nutrients, electrolytes and fluids, they require lifelong total parenteral nutrition, TPN, with or without supplemental intravenous fluids, which together comprise parenteral support, PS, for up to seven days per week and up to 20+ hours per day. As presented at ESPGHAN 2026, the results of ongoing investigations of liquid oral crofelemer demonstrate substantial reductions of PS and PS normalized to body weight in pediatric IF patients dosed orally for more than one year, with no significant clinical or laboratory abnormalities. In one MVID patient, the weekly PS requirements normalized to body weight have been reduced by up to 48% following greater than 12 months of liquid oral high-dose crofelemer therapy. In two pediatric SBS-IF patients, weekly PS requirements normalized to body weight were reduced up to 40% following greater than12 months of liquid oral high dose crofelemer therapy.